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Commodity: Oxytocin by Reproductive Health Supplies Coalition
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 Technical Reference Team 
Commodity: Oxytocin 
Including oxytocin in cold chain distribution channels is one way to help ensure its 
effectiveness. 
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Background  
The UN Commission on Life-Saving Commodities for 
Women and Children (the Commission) was formed in 
2012 by the UN Secretary-General as part of the global 
Every Woman, Every Child (EWEC) movement. EWEC 
challenges the global community to increase access to 
and appropriate use of essential medicines, medical 
devices, and health supplies that effectively address 
the leading preventable causes of death during 
pregnancy, childbirth, and childhood.  
 
Led by a wide range of high-level leaders from around 
the world, the Commission developed a framework 
for action on Reproductive, Maternal, Newborn, and 
Child Health (RMNCH) products that can be applied 
nationally and utilized in global RMNCH initiatives. The 
framework outlines a priority list of 13 commodities, 
key barriers to access and use, and 10 cross-cutting 
recommendations to rapidly increase both access and 
use. By increasing access to and use of these 13 
commodities, it is estimated that 6 million women and 
children can be saved by 2017. 
 
Moving forward 
To help carry forward the Commission’s 
recommendations at the global and national levels, 
Global Technical Reference Teams (TRT) were 
established. One group was formed for each of the 13 
commodities and 10 recommendations, and an 
advocacy working group is dedicated to advancing 
cross-cutting goals. The groups carry out their work 
through a variety of mechanisms, including guidance 
documents and tools to support countries in their 
efforts to implement recommendations and address 
global and regional bottlenecks. The TRTs are 
coordinated by a Strategy and Coordination Team 
hosted by the United Nations Children’s Fund (UNICEF).  
 
 
 
 
 
 
 
 
 
 
 
 
Spotlight on Oxytocin  
Postpartum hemorrhage (PPH) or excessive bleeding 
after childbirth is the leading cause of maternal death. 
PPH is preventable and treatable, yet one out of four 
maternal deaths is caused by this complication 
occurring after birth. Oxytocin is one uterotonic 
medicine that can prevent and treat PPH. The 
medicine’s active ingredient is the naturally occurring 
hormone oxytocin, which plays a critical role in 
childbirth by causing contractions of the uterus before, 
during, and after birth. Oxytocin is a generic drug that 
is widely distributed throughout the world and is 
packaged in ampoules or prefilled injection devices. 
However, barriers to access, quality, and regulation 
limit the maximum positive impact of oxytocin. 
 
The Maternal Health Technical Reference Team (MH 
TRT) works to increase the appropriate use of quality 
oxytocin, misoprostol and magnesium sulfate, as well 
as to improve access and use by reducing key barriers 
in EWEC countries. The MH TRT’s objectives are to: 
• Improve forecasting and quantification; 
• Achieve an adequate supply of quality 
commodities available where needed; 
• Improve and adopt practices and policies for safe 
use; 
• Support inclusion of oxytocin in the cold chain 
through advocacy and interventions; and 
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• Advance innovations such as simplified packaging 
and presentation, as well as heat-stable 
formulations and easier to use modalities.  
 
The MH TRT’s seven subgroups offer expertise to 
advance specific work streams related to one of the 
three maternal health commodities or cross-cutting 
issues. 
 
Group membership  
The lead conveners of the MH TRT are the US Agency 
for International Development (USAID) and the United 
Nations Population Fund (UNFPA). The subgroup 
conveners include: Tools-Systems for Improved Access 
to Pharmaceuticals and Services program led by 
Management Sciences for Health; Mapping of 
manufacturers-Concept Foundation; Increasing use of 
magnesium sulfate-Accelovate and MCHIP/Jhpiego; 
Oxytocin in the cold chain-USAID; Improved uptake and 
use of WHO guidelines and recommendations-PATH; 
Misoprostol on Essential Medicines Lists (EML)- 
Venture Strategies Innovation; and Commodity 
Security- John Snow, Inc. 
 
Progress to date                                                   
The MH TRT has developed numerous tools and 
resources that can be used to address issues relating to 
the three commodities. These include fact sheets on 
quantification, forecasting, product use, demand, and 
quality tools. The fact sheets describe key 
characteristics of each tool and include the purpose, 
expected outcome, type, and format of the tool. The 
fact sheets also outline the resources required to use 
the tools and the tools’ available languages. The MH 
TRT has also conducted oxytocin-specific activities. The 
group developed a list of oxytocin manufacturers and 
determined the overarching issues impacting the 
quality of oxytocin. Additionally, following a review, 
the group found no written policies or documents 
prohibiting oxytocin from being included in the cold 
chain—a key component of oxytocin quality assurance. 
 
 
 
Upcoming activities 
During the next two years, the MH TRT will:  
• Develop a knowledge translation methodology 
that will be used in three pathfinder countries 
to increase the safe and appropriate use of 
magnesium sulfate, misoprostol, and oxytocin; 
• Assist with the development of a cross-cutting, 
multi-level implementation strategy for 
improving adherence to World Health 
Organization (WHO) guidelines related to 
maternal health commodities; 
• Develop a monitoring and evaluation strategy 
for ongoing assessment of sustained guideline 
use at the national and local level;  
• Analyze the status of oxytocin manufacturers 
that have submitted WHO prequalification 
applications, and establish a business case for 
others to do the same; and 
• Develop a policy brief recommending the 
inclusion of oxytocin in the cold chain and 
support a select group of countries to include 
oxytocin in their countries.   
 
Available resources 
The MH TRT will offer the following technical 
assistance to pathfinder countries, including: 
• Assessing the market for oxytocin and existing 
public and private oxytocin manufacturers; 
• Identifying barriers to including oxytocin in the 
cold chain and opportunities for advocacy and 
policy change within specific countries;  
• Identifying barriers to implementation of WHO 
guidelines and assist countries to develop 
implementation plans to address issues, 
followed by evaluation of efforts; and 
• Establishing commodity security committees 
related to reproductive, maternal, newborn 
and child health. 
 
Contact us 
For more information or to request tools and technical 
assistance, please contact Deborah Armbruster, USAID 
(darmbruster@usaid.gov), or Jagdish Upadhyay, 
UNFPA (upadhyay@unfpa.org). 
